Phase 3 Data Demonstrate Comparability Of Epirus’ BOW015 To Remicade® For Treatment Of Rheumatoid Arthritis
6/12/2014 9:47:46 AM
PARIS--(BUSINESS WIRE)--Epirus Switzerland GmbH, a subsidiary of Boston-based Epirus Biopharmaceuticals focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced clinical data from a Phase 3 study of the efficacy and safety of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis (RA). Jonathan Kay, MD and Professor of Medicine and Director of Clinical Research in the Division of Rheumatology at UMass Memorial Medical Center and the University of Massachusetts Medical School, presented the results of this trial at the European League Against Rheumatism (EULAR) Annual Conference.
Help employers find you! Check out all the jobs and post your resume.
comments powered by